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The fluorinated pyrimidine, 5-fluorouracil (FU), has been used in the treat- 
ment of a wide variety of solid tumors for more than two decades [l] . It is 
frequently used in the treatment of early and advanced colorectal carcinomas. 
Since the drug has a short biological half-life, the clinical pharmacokinetic 
studies require a sensitive assay procedure which can quantitate low ng/ml 
FU levels in plasma. 
Several gas chromatographic (GC) and high-performance liquid chromato- 
graphic (HPLC) methods for determining plasma FU levels have been reported 
in the literature [2--193. The GC methods have employed either packed 
columns [2] or capillary columns [3] and utilized the nitrogen-phosphorus- 
selective detector. The sensitivity of the capillary GC method was reported to 
be 150 ng/ml FU. Another GC procedure described in the literature requires 
derivatization of FU before analysis [9]. Several gas chromatographic- -mass 
spectrometric (GC-MS) assays for FU have also been reported [4, 16-191 
which are both sensitive and specific, but the complexities of the assays and 
associated instrumentation prohibit their routine use. A HPLC method re- 
ported in the literature suffered from poor reproducibility [5], which was 
probably due to adsorption of FU on glass surfaces [8] . Modification of this 
assay has been reported to improve its reproducibility [6] but the assay em- 
ploys thymidine as the internal standard which is endogenous in plasma. 
Another HPLC assay employed back-extraction of the organic extract into 
phosphate buffer (pH=ll), followed by neutralization with sulfuric acid, but 
the internal standard, 5-fluorocytosine, coeluted with an endogenous peak in 
blank (control) plasma [ 71. 
The assay procedure described in this report can attain detection limits 
around 25 ng/ml and is routinely used in the FU concentration range of 50- 
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2000 ng/ml. Both internal standard (5-chlorouracil, CU) and drug (FU) show 
no interference by coeluting endogenous or exogenous compounds in the 
several hundreds of patient samples already analyzed using this procedure. Al- 
though primarily designed for plasma assays, this procedure has been used for 
the determination of FU levels in peritoneal fluid as well (see Fig. 2). 
EXPERIMENTAL 
Reagents 
Ethyl acetate and methanol (Burdick & Jackson Labs., Muskegon, MI, 
U.S.A.), monobasic ammonium phosphate (J.T. Baker, Phillipsburg, NJ, 
U.S.A.), potassium hydroxide and ammonium sulfate (Mallinckrodt, St. Louis, 
MO, U.S.A.), 5-chlorouracil (Sigma, St. Louis, MO, U.S.A.), and 5-fluorouracil 
(Roche Labs., Nutley, NJ, U.S.A.) were used. 
Stock solutions 
A 5-fluorouracil solution (0.10 mg/ml in methanol), and a 5-chlorouracil 
solution (1.0 mg/ml in methanol) were prepared and stored at -20°C. Saturated 
ammonium sulfate solution and 0.5 M potassium hydroxide solution were pre- 
pared and stored at room temperature. 
Standards 
The FU stock solution was diluted 1:lO with water to yield the FU standard 
solution containing 10 pg/ml. The CU stock solution was diluted with water to 
yield the internal standard solution containing 10 ccg CU per ml. 
Quality-control samples at two concentrations (200 and 2000 ng/ml FU) 
were prepared by spiking blank plasma with the appropriate volumes of the FU 
standard. After mixing, l.O-ml aliquots were transferred to glass tubes, tightly 
capped, and stored frozen at -30°C. Three quality-control samples of each con- 
centration were included with every group of experimental samples to be 
analyzed. 
Chromatographic conditions 
The HPLC unit included a Waters Assoc. Model 6000A solvent delivery 
system, a Waters Assoc. Model 440 UV-VIS absorbance detector with a 254~nm 
filter, a Waters Assoc. Model 710B WISP autosampler and a Hewlett-Packard 
Model 3390A integrator. The column used was a DuPont Zorbax CB reversed- 
phase column (25 cm X 4.6 mm I.D., spherical, 6 pm particle size). The mobile 
phase was a 0.05 M ammonium phosphate buffer (pH 6.8)-methanol mixture 
with a final methanol concentration of 2% (v/v). The flow-rate was set at 1.0 
ml/mm 
Under these conditions the retention times of FU and CU were 4.4 and 
7.6 min, respectively. 
Sample preparation 
To glass tubes (15 ml capacity) were added 1.0 ml plasma, 100 ~1 internal 
standard solution (1000 ng CU), 2.0 ml saturated ammonium sulfate solution, 
100 ~1 ammonium phosphate buffer, pH 6.7 and 8.0 ml ethyl acetate. The 
tubes were tightly capped and shaken for 15 min at room temperature. In un- 
387 
known plasma samples where drug concentrations were expected to exceed 
2000 ng/ml, a smaller volume was utilized with the difference to 1.0 ml made 
up with an appropriate volume of blank plasma. After centrifugation (room 
temperature) for 10 min at 1200 g, the ethyl acetate phase was transferred to 
clean conical-bottomed glass tubes and concentrated to approximately 1.0 ml 
by evaporation in a water-bath (45°C) under a stream of air. To each sample 
were added 400 ~1 of 0.5 M potassium hydroxide and the drug and internal 
standard back-extracted by shaking for 15 min at room temperature. After cen- 
trifugation (room temperature) at 1000 g for 10 min, the ethyl acetate phase 
was removed by aspiration. Volumes of 3.0-30.0 ~1 of the alkaline aqueous 
phase were injected for HPLC analysis. 
Standard calibration curve 
Blank plasma samples were spiked in duplicate with the appropriate volumes 
of the FU standard solution to concentrations ranging from 0 to 2000 ng/ml 
and subjected to the sample preparation procedure described above. Calibration 
curves were run (in duplicate) with each set of experimental samples. 
Calculations 
Calibration curves were constructed by plotting the ratio of the peak height 
of FU to that of the internal standard as a function of the plasma drug concen- 
tration. The best-fit straight line was determined using the method of least 
squares. The FU concentrations of unknown samples were calculated from the 
least-squares regression line of the calibration curve. 
RESULTS AND DISCUSSION 
Under the described conditions, the retention times of FU and CU were 4.4 
and 7.6 min, respectively. Fig. 1 illustrates typical chromatograms for control 
plasma (no internal standard added), a quality-control sample containing 
200 ng/ml FU in plasma, and a patient plasma sample containing 750 ng/ml FU. 
The plasma samples elicit no interfering peaks. The total analysis time required 
II- 
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Fig. 1. Typical chromatograms of (a) control plasma without added internal standard, (b) a 
quality-control sample containing 200 ng/ml FU in plasma, and (c) a plasma sample obtained 




FLUOROURACIL CONCENTRATIONS IN CONTROL SAMPLES SEEDED WITH 200 
AND 2000 ng/ml ASSAYED OVER A THREE-DAY PERIOD 
Day Concentration (ng/ml) 
200 ng/ml 2000 ng/ml 
1 200.4 2125.5 
240.6 2062.3 
238.3 2207.4 
2 202.2 2014.5 
229.7 1955.4 
234.6 1855.5 
3 200.2 1935.0 
225.1 1977.7 
203.3 2015.8 
Mean f S.D. (nglml) 
Coefficient of variation (%) 
Percentage from theoretical 
219.4 f 17.5 2016.6 + 105.0 
8.0 5.2 
+9.7 +0.8 
for each run was 15 min. The validity of the assay procedure was established 
through a careful study of the linearity of response, reproducibility, accuracy 
and precision. 
The peak-height ratio was directly proportional to the FU concentrations 
over the range 50-2000 ng/ml. The best-fit lines were obtained using linear 
regression analysis. To test the reproducibility of this procedure, calibration 
samples were prepared in triplicate on three successive days. Triplicate quality- 
control samples at each concentration (200 and 2000 ng/ml) were run in 
parallel. The results of the linear regression analyses of this data were: y = 
(0.00125 * 0.00005)~ + (0.043 + 0.015), (r=0.998 f 0.001). 
The accuracy and precision of the method were assessed by seeding plasma 
at 5-FU concentrations of 200 and 2000 ng/ml. Triplicate quality-control sam- 
ples at each concentration were assayed on each of three consecutive days. 
Table I gives the results of this experiment. The precision of the assay was 
found to have coefficients of variation (C.V.) ranging from 5.2 to 8.0%. The 
concentration means for the seeded control samples were found to be within 
OS-9.7% of the theoretical values for FU. 
Application of the method developed was demonstrated by measuring the 
plasma and peritoneal fluid FU levels in a patient following the intraperitoneal 
infusion of 1.0 g FU per day for four days. Peripheral venous and peritoneal 
fluid samples were withdrawn at regular intervals and the samples obtained 
were used for drug analysis. Fig. 2 illustrates the plasma and peritoneal fluid 
FU concentrations versus time plots from this experiment. As shown in Fig. 2, 
the peritoneal fluid FU steady-state levels attained in this infusion were 
approximately 200-fold greater than the corresponding peripheral venous 
plasma FU levels. 
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Fig. 2. The plasma and peritoneal fluid FU concentration -time profile of a patient follow- 
ing intraperitoneal infusion of 1.0 g FU per day for four days. (0) Peritoneal fluid levels; 
(0 ) plasma levels. 
This HPLC assay method for plasma 5FU has been utilized in our laboratory 
in the determination of FU levels in several hundred patient and animal 
samples. It has proved dependable, rapid, accurate and sensitive. Unlike pre- 
viously published HPLC 5-FU procedures [5-7, 10-151, it does not suffer 
from sensitivity limitations [ 111, it does not employ as an internal standard a 
compound endogenous to plasma [6], it does not necessitate derivatization of 
the FU before analysis [12], it is not hampered by incomplete chromato- 
graphic resolution of the FU peak from surrounding endogenous peaks 1’7, 13, 
151, it does not necessitate the use of radiolabelled drug as internal standards 
[ 141, and it does not include extra steps in the sample preparation procedure 
to neutralize the final solution to be injected for HPLC analysis [7, lo]. This 
procedure has been successfully utilized in numerous pharmacokinetic studies 
involving this important antineoplastic agent. 
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